340binformed.org

Your Free Source for 340B News and Commentary

  • About us
  • Advertise
  • Contact
  • 340B Health

National Newspaper Ad Hits Genentech’s Specialty-Drug Switch

Open letter in The New York Times calls for reversal of "ill-advised" change
 

Print Article

November 24, 2014—A leading hospital group purchasing organization and 16 prominent health care institutions asked Genentech in an open letter in The New York Times yesterday to reverse its “ill-advised decision” to move its top-selling cancer drugs Avastin, Herceptin, and Rituxan into the more expensive specialty distribution channel.  


You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register.    Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

LATEST ARTICLES DELIVERED

Get new article alerts via email.

This field is required.

Check your inbox or spam folder now to confirm your subscription.

FOLLOW | SHARE | LIKE

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

340B Health Twitter

Twitter feed is not available at the moment.

RSS feed: 340B Employed 340B Employed

  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Specialist | Vail Health November 17, 2026
  • Pharmacy Manager, 340B Program | Tufts Medical Center November 11, 2026
  • 340B Program Pharmacy Manager | Allies for Health + Wellbeing November 10, 2026

Copyright © 2026 · 340B Health